[go: up one dir, main page]

WO2004050848A3 - Procedes de masquage d'antigene de globules rouges permettant de reduire une hemolyse - Google Patents

Procedes de masquage d'antigene de globules rouges permettant de reduire une hemolyse Download PDF

Info

Publication number
WO2004050848A3
WO2004050848A3 PCT/US2003/038224 US0338224W WO2004050848A3 WO 2004050848 A3 WO2004050848 A3 WO 2004050848A3 US 0338224 W US0338224 W US 0338224W WO 2004050848 A3 WO2004050848 A3 WO 2004050848A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
rbc
blood cells
red blood
antigen masking
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/038224
Other languages
English (en)
Other versions
WO2004050848A2 (fr
Inventor
Adonis Stassinopoulos
Basha Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cerus Corp
Original Assignee
Cerus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerus Corp filed Critical Cerus Corp
Priority to AU2003302499A priority Critical patent/AU2003302499A1/en
Publication of WO2004050848A2 publication Critical patent/WO2004050848A2/fr
Publication of WO2004050848A3 publication Critical patent/WO2004050848A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des procédés pour préparer une composition de globules rouges qui présente une antigénicité nettement réduite. Ces procédés consistent à optimiser des conditions de réaction pour lier des composés de masquage d'antigène aux globules rouges, sans modifier de manière importante le fonctionnement de ces globules rouges, ce qui permet notamment de réduire l'hémolyse des globules rouges résultant d'un traitement de ceux-ci. Les compositions de globules rouges sont notamment utilisées pour être administrées à un individu chez lequel le potentiel d'une réaction immunitaire est élevé, par exemple chez des receveurs de sang allo-immunisés ou dans des situations de trauma où la possibilité d'une transfusion d'unité de sang non appropriée est plus élevée. Les compositions de globules rouges selon cette invention permettent de réduire nettement le risque d'une réaction immunitaire associée à une transfusion.
PCT/US2003/038224 2002-12-04 2003-12-03 Procedes de masquage d'antigene de globules rouges permettant de reduire une hemolyse Ceased WO2004050848A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003302499A AU2003302499A1 (en) 2002-12-04 2003-12-03 Methods for antigen masking of red blood cells resulting in reduced hemolysis

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US43121302P 2002-12-04 2002-12-04
US43121602P 2002-12-04 2002-12-04
US43121502P 2002-12-04 2002-12-04
US43121402P 2002-12-04 2002-12-04
US60/431,215 2002-12-04
US60/431,214 2002-12-04
US60/431,216 2002-12-04
US60/431,213 2002-12-04

Publications (2)

Publication Number Publication Date
WO2004050848A2 WO2004050848A2 (fr) 2004-06-17
WO2004050848A3 true WO2004050848A3 (fr) 2004-12-09

Family

ID=32475715

Family Applications (4)

Application Number Title Priority Date Filing Date
PCT/US2003/038262 Ceased WO2004050029A2 (fr) 2002-12-04 2003-12-03 Nouveaux composes de polyethylene glycol actives
PCT/US2003/038270 Ceased WO2004049914A2 (fr) 2002-12-04 2003-12-03 Procedes destines a faire reagir un compose de masquage d'antigenes avec des erythrocytes presentant une efficacite elevee
PCT/US2003/038349 Ceased WO2004050897A2 (fr) 2002-12-04 2003-12-03 Procedes de preparation de globules rouges a masquage d'antigene et hemolyse reduite au moyen de serums
PCT/US2003/038224 Ceased WO2004050848A2 (fr) 2002-12-04 2003-12-03 Procedes de masquage d'antigene de globules rouges permettant de reduire une hemolyse

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PCT/US2003/038262 Ceased WO2004050029A2 (fr) 2002-12-04 2003-12-03 Nouveaux composes de polyethylene glycol actives
PCT/US2003/038270 Ceased WO2004049914A2 (fr) 2002-12-04 2003-12-03 Procedes destines a faire reagir un compose de masquage d'antigenes avec des erythrocytes presentant une efficacite elevee
PCT/US2003/038349 Ceased WO2004050897A2 (fr) 2002-12-04 2003-12-03 Procedes de preparation de globules rouges a masquage d'antigene et hemolyse reduite au moyen de serums

Country Status (2)

Country Link
AU (4) AU2003302499A1 (fr)
WO (4) WO2004050029A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10799533B2 (en) 2015-10-23 2020-10-13 Cerus Corporation Plasma compositions and methods of use thereof
US11096963B2 (en) 2015-06-26 2021-08-24 Cerus Corporation Cryoprecipitate compositions and methods of preparation thereof
US11235090B2 (en) 2017-03-03 2022-02-01 Cerus Corporation Kits and methods for preparing pathogen-inactivated platelet compositions
US11554185B2 (en) 2017-12-29 2023-01-17 Cerus Corporation Systems and methods for treating biological fluids
US11883544B2 (en) 2019-06-28 2024-01-30 Cerus Corporation System and methods for implementing a biological fluid treatment device
US12011510B2 (en) 2019-06-22 2024-06-18 Cerus Corporation Biological fluid treatment systems
US12282015B2 (en) 2016-12-23 2025-04-22 Cerus Corporation Systems and methods for testing and screening using compound bound substrates

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521174B2 (en) * 2003-12-05 2009-04-21 Albert Einstein College Of Medicine Of Yeshiva University Universal red blood cells, methods of preparing same, and uses thereof
CN102108119A (zh) 2009-12-25 2011-06-29 天津键凯科技有限公司 多臂聚乙二醇衍生物及其与药物的结合物和凝胶
CA3244923A1 (fr) * 2022-03-07 2023-09-14 Icoat Medical Ab Nouvelle utilisation de molécules de peg-phospholipide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312685B1 (en) * 1998-03-13 2001-11-06 Timothy C. Fisher Red blood cells covalently bound with two different polyethylene glycol derivatives
WO2001091775A2 (fr) * 2000-05-31 2001-12-06 Cerus Corporation Preparation d'une solution de globules rouges a antigenicite reduite contenant des agents pathogenes inactives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL292906A (fr) * 1962-10-30

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312685B1 (en) * 1998-03-13 2001-11-06 Timothy C. Fisher Red blood cells covalently bound with two different polyethylene glycol derivatives
WO2001091775A2 (fr) * 2000-05-31 2001-12-06 Cerus Corporation Preparation d'une solution de globules rouges a antigenicite reduite contenant des agents pathogenes inactives

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11096963B2 (en) 2015-06-26 2021-08-24 Cerus Corporation Cryoprecipitate compositions and methods of preparation thereof
US10799533B2 (en) 2015-10-23 2020-10-13 Cerus Corporation Plasma compositions and methods of use thereof
US12282015B2 (en) 2016-12-23 2025-04-22 Cerus Corporation Systems and methods for testing and screening using compound bound substrates
US11235090B2 (en) 2017-03-03 2022-02-01 Cerus Corporation Kits and methods for preparing pathogen-inactivated platelet compositions
US12064537B2 (en) 2017-03-03 2024-08-20 Cerus Corporation Kits and methods for preparing pathogen-inactivated platelet compositions
US11554185B2 (en) 2017-12-29 2023-01-17 Cerus Corporation Systems and methods for treating biological fluids
US12214092B2 (en) 2017-12-29 2025-02-04 Cerus Corporation Systems and methods for treating biological fluids
US12011510B2 (en) 2019-06-22 2024-06-18 Cerus Corporation Biological fluid treatment systems
US11883544B2 (en) 2019-06-28 2024-01-30 Cerus Corporation System and methods for implementing a biological fluid treatment device
US12343436B2 (en) 2019-06-28 2025-07-01 Cerus Corporation System and methods for implementing a biological fluid treatment device

Also Published As

Publication number Publication date
AU2003298827A1 (en) 2004-06-23
AU2003302499A1 (en) 2004-06-23
WO2004049914A2 (fr) 2004-06-17
AU2003298827A8 (en) 2004-06-23
WO2004050897A3 (fr) 2004-08-26
AU2003297614A1 (en) 2004-06-23
WO2004049914A3 (fr) 2005-02-24
WO2004050848A2 (fr) 2004-06-17
AU2003293237A8 (en) 2004-06-23
WO2004050029A3 (fr) 2004-10-21
AU2003297614A8 (en) 2004-06-23
WO2004050897A2 (fr) 2004-06-17
WO2004050029A2 (fr) 2004-06-17
AU2003302499A8 (en) 2004-06-23
AU2003293237A1 (en) 2004-06-23

Similar Documents

Publication Publication Date Title
WO2003047650A3 (fr) Preparation de globules rouges a pouvoir antigenique reduit
WO2001074158A3 (fr) Systemes et procedes pour collecter des composants sanguins sans leucocytes, comprenant le plasma exempt ou pratiquement exempt d'especes sanguines cellulaires
WO2001091775A3 (fr) Preparation d'une solution de globules rouges a antigenicite reduite contenant des agents pathogenes inactives
EP2722387A3 (fr) Endoderme définitif
AU9058091A (en) Preparation of nucleic acid samples
WO2004084825A3 (fr) Composition cicatrisante derivee de plasma a faible concentration de plaquettes
WO2004050848A3 (fr) Procedes de masquage d'antigene de globules rouges permettant de reduire une hemolyse
MXPA05007888A (es) Coagulante autologo y homologo producido a partir de sangre entera anticoagulada.
WO2003076490A8 (fr) Derive polymere hydrophile a ramification de type y et procede de preparation d'un composite medical contenant le compose precite
MXPA06001821A (es) Una composicion probiotica, liquida, estable, preparacion y aplicaciones de la misma.
WO2005025615A3 (fr) Anticorps specifiques de facteur ixa presentant une activite assimilee au facteur viiia
CA2407961A1 (fr) Systeme automatise et procede permettant d'extraire des composes contenus dans le sang
Matar et al. Down regulation of T-cell-derived IL-10 production by low-dose cyclophosphamide treatment in tumor-bearing rats restores in vitro normal lymphoproliferative response
WO2005021706A3 (fr) Administration de composes avec des cellules sanguines rehydratees
WO2003045427A3 (fr) Composition pharmaceutique servant a induire une reponse immune chez l'homme ou chez l'animal
WO2005030040A3 (fr) Identification et isolation de cellules souches hematopoietiques
WO2006023502A3 (fr) Dispositif et compositions de separation de particules / de cellules
WO2000044398A3 (fr) Procedes d'augmentation de plaquettes circulantes pour prelevement et cryoconservation avec des compositions de thrombopoietine
MY124727A (en) Tri-substituted phenyl derivatives and analogues.
WO2000057909A3 (fr) Vaccin a base de virus de dengue-2 attenue
AUPQ486699A0 (en) A method of treating infectious diseases
Haag-Weber et al. Impaired cellular host defence in peritoneal dialysis by two granulocyte inhibitory proteins
WO2003061611A3 (fr) Composition cosmetique longue tenue comprenant un materiau pro-adhesif et un compose diffusant separes
ES8301274A1 (es) Procedimiento microbiologico para la obtencion de un nuevo compuesto antibiotico de la cepa streptomyces.
EP1504766A4 (fr) Composition support de medicament ou de gene avec activite d'hemagglutinine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP